bioAffinity Technologies, Inc.
BIAF Nasdaq· Services-Commercial Physical & Biological Research
Last close · Oct 23, 2026
$2.80
KIRA · Stoqly’s AI analyst, in plain words
- bioAffinity Technologies, Inc. had $6.2M of revenue in fiscal 2025, down 34.2% on the year before.
- Its operating margin was −171.6%, down 75.9 pts: of every 100 in sales, about −172 is left after running the business.
- bioAffinity Technologies, Inc. lost $14.9M in fiscal 2025.
- Free cash flow was −$9.4M in fiscal 2025, −152.4% of revenue.
Market cap
$14.6M
P/E
—
Revenue
$6.2M
Net income
−$14.9M
Free cash flow
−$9.4M
Operating margin
−171.6%
bioAffinity Technologies, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−34.2%
No. Sales fell 34.2% last year.
Does it make a profit?
−242.0%
No. It lost money last year.
Does profit turn into cash?
−152.4%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What bioAffinity Technologies, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 16, 2026
- Legal name
- bioAffinity Technologies, Inc.
- CIK
- 0001712762
bioAffinity Technologies, Inc. · BIAF
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | $6.9M | $7.9M | $9.4M | $6.2M |
| Revenue growth | — | — | 14.5% | 18.5% | −34.2% |
| Gross margin | — | 0.1% | — | — | — |
| Operating margin | — | −58.1% | −100.9% | −95.6% | −171.6% |
| Net income | −$6.3M | −$8.2M | −$7.9M | −$9.0M | −$14.9M |
| Net margin | — | −118.2% | −100.5% | −96.6% | −242.0% |
| Diluted EPS | — | −$1.81 | −$0.91 | −$22.50 | −$8.66 |
| Cash | |||||
| Cash from operations | −$2.0M | −$4.1M | −$6.0M | −$7.3M | −$9.3M |
| Capital expenditure | — | $0.2M | $0.0M | $0.1M | $0.1M |
| Free cash flow | — | −$4.3M | −$6.1M | −$7.3M | −$9.4M |
| FCF margin | — | −62.2% | −76.7% | −78.4% | −152.4% |
| Share count change | — | — | 94.4% | −95.4% | 325.8% |
| Debt and strength | |||||
| Cash and short-term investments | $1.4M | $11.4M | $2.8M | $1.1M | $6.4M |
| Shareholders' equity | −$15.8M | $11.0M | $4.9M | $2.6M | $7.3M |
| Current ratio | 0.1x | 10.5x | 1.8x | 0.9x | 2.6x |
| Interest coverage | −2.2x | −1.6x | −214.9x | −96.8x | −238.1x |
| Returns and quality | |||||
| Return on equity | — | — | −99.8% | −242.4% | −301.8% |
| Return on tangible equity | — | −73.8% | −303.3% | −2,140.1% | −289.2% |
| Piotroski F-score | — | — | 2 | 3 | 3 |
| Altman Z'' | −127.8 | 4.0 | −21.3 | −35.8 | −22.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
bioAffinity Technologies, Inc. · BIAF
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.80 a share, the company is worth $14.6M.
Source: SEC EDGAR XBRL filings (CIK 0001712762). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.